The EU Clinical Trials Regulation: Key Priorities, Purposes and Aims and the Implications for Public Health

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
1239 Downloads (Pure)

Abstract

The replacement of the European Union (EU) Clinical Trials Directive by the new Clinical Trials Regulation (CTR), which entered into force on 16 June 2014 but will not apply before 28 May 2016, provides an opportunity to review the legal and political context within which this important aspect of research law and policy sits and to reflect on the implications for public health. My aim in this article is to relate the context to the key purposes and aims of EU law and policy on clinical trials in order to explain and clarify its orientation. On that basis, I argue that the CTR and the changes it introduces to the law on clinical trials are part of the EU's continued focus on market optimisation. It is this focus that orients and directs the wider pharmaceutical development pipeline, but that undermines the achievement of key public health objectives.
Original languageEnglish
Pages (from-to)192-198
Number of pages7
JournalJournal of Medical Ethics
Volume42
Issue number3
Early online date01 Feb 2016
DOIs
Publication statusPublished - Mar 2016

Fingerprint Dive into the research topics of 'The EU Clinical Trials Regulation: Key Priorities, Purposes and Aims and the Implications for Public Health'. Together they form a unique fingerprint.

Cite this